Breaking News

Sage Therapeutics Restructures to Support ZURZUVAE Launch

Plans to cut 40% of workforce to help achieve sustained growth and allow for commercial hires.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sage Therapeutics, Inc. is reorganizing its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with postpartum depression (PPD) in late 2023. Following a strategic review, the company will refine pipeline development efforts to advance SAGE-718 and SAGE-324, as well as pause certain earlier-stage programs, implement a ~40% workforce reduction to help achieve sustained growth and allow for co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters